11/28
01:16 am
ipha
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 [Yahoo! Finance]
Low
Report
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 [Yahoo! Finance]
11/28
01:00 am
ipha
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
Low
Report
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
11/17
01:25 am
ipha
Innate Pharma to Present at Jefferies Global Healthcare Conference [Yahoo! Finance]
Low
Report
Innate Pharma to Present at Jefferies Global Healthcare Conference [Yahoo! Finance]
11/17
01:00 am
ipha
Innate Pharma to Present at Jefferies Global Healthcare Conference
Low
Report
Innate Pharma to Present at Jefferies Global Healthcare Conference
11/13
01:06 am
ipha
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results [Yahoo! Finance]
Medium
Report
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results [Yahoo! Finance]
11/13
01:00 am
ipha
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
Medium
Report
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
11/10
01:16 am
ipha
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL [Yahoo! Finance]
High
Report
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL [Yahoo! Finance]
11/10
01:00 am
ipha
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
High
Report
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
11/5
01:00 am
ipha
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
Low
Report
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
10/30
10:47 am
ipha
Innate Pharma (NASDAQ:IPHA) was upgraded by analysts at HC Wainwright from a "hold" rating to a "strong-buy" rating.
Low
Report
Innate Pharma (NASDAQ:IPHA) was upgraded by analysts at HC Wainwright from a "hold" rating to a "strong-buy" rating.
10/29
08:08 am
ipha
Innate Pharma (NASDAQ:IPHA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.
Neutral
Report
Innate Pharma (NASDAQ:IPHA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.
10/29
07:09 am
ipha
Innate Pharma (NASDAQ:IPHA) was given a new $5.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
Medium
Report
Innate Pharma (NASDAQ:IPHA) was given a new $5.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
10/14
01:25 am
ipha
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 [Yahoo! Finance]
Low
Report
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 [Yahoo! Finance]
10/14
01:00 am
ipha
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
Low
Report
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
9/21
04:25 am
ipha
How the Narrative Around Innate Pharma Is Shifting After Recent Strategic Decisions [Yahoo! Finance]
Low
Report
How the Narrative Around Innate Pharma Is Shifting After Recent Strategic Decisions [Yahoo! Finance]
9/19
06:25 am
ipha
Innate Pharma (NASDAQ:IPHA) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Medium
Report
Innate Pharma (NASDAQ:IPHA) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
9/18
08:09 am
ipha
Innate Pharma (NASDAQ:IPHA) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Innate Pharma (NASDAQ:IPHA) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
9/18
08:09 am
ipha
Innate Pharma (NASDAQ:IPHA) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $2.00 price target on the stock, down previously from $10.00.
Low
Report
Innate Pharma (NASDAQ:IPHA) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $2.00 price target on the stock, down previously from $10.00.
9/17
01:17 am
ipha
Innate Pharma Reports First Half 2025 Business Update and Financial Results [Yahoo! Finance]
Neutral
Report
Innate Pharma Reports First Half 2025 Business Update and Financial Results [Yahoo! Finance]
9/17
01:00 am
ipha
Innate Pharma Reports First Half 2025 Business Update and Financial Results
Medium
Report
Innate Pharma Reports First Half 2025 Business Update and Financial Results
9/15
01:00 am
ipha
Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
Medium
Report
Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
9/10
04:30 am
ipha
Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update
Medium
Report
Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update